Diagnos (TSE:ADK)
:ADK
Want to see TSE:ADK full AI Analyst Report?
ADK Stock Chart & Stats
C$0.36
C$0.03(9.38%)
At close: 4:00 PM EST
C$0.36
C$0.03(9.38%)
Day’s Range― - ―
52-Week RangeC$0.18 - C$0.42
Previous CloseN/A
Volume270.50K
Average Volume (3M)342.67K
Market Cap
C$25.89M
Enterprise ValueC$25.03M
Total Cash (Recent Filing)C$3.40M
Total Debt (Recent Filing)C$2.00M
Price to Earnings (P/E)―
Beta0.55
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding120,412,550
10 Day Avg. Volume531,548
30 Day Avg. Volume342,665
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)-6.56
Price to Sales (P/S)117.69
P/FCF Ratio-9.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
AI-driven Retinal Screening (CARA)Diagnos’ CARA platform is a focused AI/image-analysis product for retinal screening, a durable healthcare need. A software-driven screening tool scales with volume, embeds into screening workflows, and can create persistent demand from clinics and programs managing chronic eye-disease screening.
Commercial SaaS-like Revenue ModelThe company monetizes CARA via access to its analysis service in organized screening workflows. That commercial model is structurally scalable: revenue grows with screening volume or contracts, enabling recurring income potential if adoption expands and per-test or contract economics improve over time.
Lean Operating FootprintA small headcount implies low fixed payroll overhead relative to commercial software peers, which preserves the potential for margin expansion if revenue recovers. For an AI software platform, low employee fixed costs support capital-efficient scaling of service capacity and deployments.
Bears Say
Declining Revenue TrendRevenue contraction over trailing periods signals adoption or commercialization challenges. Persistent top-line declines undermine operating leverage for a software service business, delaying margin recovery and making it harder to cover fixed costs and invest in market expansion.
Persistent Negative Cash FlowConsistent negative OCF and FCF reflects ongoing cash burn and reliance on external financing. That limits the firm’s ability to self-fund commercialization, increases dilution/refinancing risk, and constrains durable investment in product improvement or sales capacity.
High Leverage Vs. Thin Equity CushionDebt sized relative to small, volatile equity creates refinancing and solvency risk given ongoing losses. A thin equity cushion limits financial flexibility to absorb continued negative results, raising structural funding risk if operating performance does not improve.
Diagnos News
ADK FAQ
What was Diagnos’s price range in the past 12 months?
Diagnos lowest stock price was C$0.17 and its highest was C$0.41 in the past 12 months.
What is Diagnos’s market cap?
Diagnos’s market cap is C$25.89M.
When is Diagnos’s upcoming earnings report date?
Diagnos’s upcoming earnings report date is Aug 20, 2026 which is in 74 days.
How were Diagnos’s earnings last quarter?
Currently, no data Available
Is Diagnos overvalued?
According to Wall Street analysts Diagnos’s price is currently Overvalued.
Does Diagnos pay dividends?
Diagnos does not currently pay dividends.
What is Diagnos’s EPS estimate?
Diagnos’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Diagnos have?
Diagnos has 120,412,550 shares outstanding.
What happened to Diagnos’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Diagnos?
Currently, no hedge funds are holding shares in TSE:ADK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Diagnos
DIAGNOS Inc. provides software-based services primarily in Canada, the United States, Colombia, Spain, Mexico, Saudi Arabia, and Costa Rica. The company offers healthcare services through Computer Assisted Retina Analysis, a web-based software tool that assists healthcare professionals for the detection of diabetic retinopathy; and allows eye care specialist to visualize both normal retinal landmarks and pathological changes. It also provides various consulting services in the fields of data analysis and artificial intelligence. The company was founded in 1998 and is headquartered in Brossard, Canada.
Technical Analysis
Rocket Doctor AI
―
Comprehensive Healthcare Systems Inc
―
UniDoc Health Corp
―
PanGenomic Health, Inc. Class A
―
DiagnaMed Holdings Corp.
―
Options Prices
Currently, No data available
---